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Abstract
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a
group of debilitating neurodegenerative disorders that affect both humans and animals.
They can be spread by horizontal transmission as seen in chronic wasting disease in
deer and elk population. In addition, transmission to humans has also been documented
which includes bovine spongiform encephalopathy in cattle to variant Creutzfeldt-Jakob
disease in humans due to consumption of contaminated meat. The most probable
natural route of transmission is by oral consumption of infectious material. Even
though this mode of transmission has been known for a long time it is still unclear how
the infectious material distributes in vivo shortly after ingestion and what is the
metabolic stability in gastro-intestinal tissues.

In this line, our hypothesis is that

infectious prions resist gastro-intestinal digestion and directly cross the intestinal barrier
after per-oral administration, distributing in blood and various organs. In order to test
this hypothesis, we characterized the metabolic profile of prions in gastro-intestinal tract
tissues by in vitro experiments and determined the initial distribution of infectious
material within hours of ingestion in vivo. Our results showed the radiolabeled
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PrPSc undergoes limited metabolic degradation -mostly in duodenum, jejunum and
ileum tissue homogenates- as compared to stomach and colon homogenates where little
degradation is observed. We have also separately shown that within two hours of oral
iii

ingestion of prions in mice self propagating prions are detected in blood, brain and
various tissues.
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CHAPTER 1
Introduction
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Prion diseases also known as transmissible spongiform encephalopathies
(TSE’s) are a group of infectious, debilitating and fatal neurodegenerative diseases
affecting both animals and humans (Prusiner, 1998). Currently, there is no cure for
these diseases and positive diagnosis is made after death by brain autopsy. In humans
one in a million cases per year globally are reported and can be inherited due to
mutation in prion protein gene (<5%), sporadic without any known etiology (>95%), or
acquired (<1%). The latter comprises both human to human (iatrogenic) or animal to
human (variant CJD) transmissions. Although rare, these diseases remain intriguing
due to the unique nature of infectious agents composed largely of misfolded proteins
known as prions (Prusiner et al., 1983). Prions were defined more than three decades
ago by Dr. Stanley Prusiner as small proteinaceous infectious particles that resist
inactivation by most procedures that modify nucleic acids (Prusiner, 1982). In contrast
to other infectious agents, like bacteria and viruses, prions resist inactivation by many
conventional chemical treatments, ultraviolet radiation, heat, and nucleases (Gajdusek
et al., 1977; Prusiner, 1982). The infectious prion protein (PrPSc) forms as the result of
a post-translational process that modifies the conformation of the endogenous cellular
PrP (PrPC) into PrPSc (Borchelt et al., 1990; Caughey & Raymond, 1991). As a result of
the misfolding process, PrPC that is composed mainly of alpha helices undergoes a
conformational change to intermolecular beta sheet as reported in PrPSc (Pan et al.,
1993). In various prion diseases the clinical characteristics differ but they all share a
common neuropathology which includes prion protein aggregate deposition, dendritic
and synaptic loss, extensive spongiform brain degeneration, atypical inflammation and
widespread neuronal death (Figure 1)(Budka, 2003; Soto & Satani, 2011) .
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Figure 1. Multiple neurodegenerative pathways are involved in prion diseases.
Sc
Brain abnormalities include PrP deposition, synaptic and dendrite loss,
spongiform degeneration, brain inflammation and neuronal death. Prion
deposition was determined by IHC staining with anti-PrP antibodies. The prion
infected animal brain (upper) and normal uninfected (lower) is shown
Reproduced, with permission, (Soto & Satani, 2011) (Copyright National
Academy of Sciences, USA).
Permission and license granted to use figure and legend in thesis from Elsevier
and National Academy of Sciences.
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1. Transmission of prion diseases in animals and humans
Some prion diseases that are known to spread by oral transmission in animals
include scrapie in sheep and goat, chronic wasting disease (CWD) in deer and elk,
bovine spongiform encephalopathy (BSE) in cattle, Kuru and variant Creutzfeldt-Jakob
disease (vCJD) in humans (Brown, 2009).
1.1 Animal Prion Diseases
1.1.1 Scrapie
Scrapie is the most studied TSE and its history goes back to 1700’s where it was
first reported in England by M’Gowan in 1710 (Plummer, 1946). This is a natural prion
disease that can affect sheep and goat. Initial transmission studies done by Dammann
in 1869, M’Fadyean in 1918 and Bertrand et al., in 1937 were negative as these studies
failed to follow the long incubation period required for disease progression (Plummer,
1946). However, once the long incubation period for this disease was recognized it was
shown to be transmissible to goats (Cuille and Chelle, 1936) and later by accidental
transmission to sheep herd by administration of a contaminated vaccine (Gordon, 1946).
Histopathologically, Brownlee in 1940 reported the presence of large vacuoles in
medulla and spinal cord of all animals affected with scrapie (Plummer, 1946).
Hallmark clinical symptoms of scrapie included intensive skin irritation caused by
itching, rubbing and scratching which resulted in the animal rubbing itself against the
posts, followed by motor and sensory impairments leading to ataxia or complete
paralysis (Plummer, 1946). Environmental transmission was observed when unaffected
sheep acquired the disease when grazed on pastures in previous contact with affected
4

animals (Plummer, 1946). To date, oral exposure of the contaminated agent has been
shown to be a major route of entry for the infectious agent ( Andreoletti et al., 2000;
Greenlee & Greenlee, 2015; Gough K.C. 2010 and van Keulen et.al., 2002). However,
recently, classical scrapie has been shown to be transmitted to cynomolgus macaque
(which is the preferred animal model to study human prion diseases) after long
incubation periods (Comoy et al., 2015).
1.1.2

Chronic Wasting Disease (CWD)

Chronic wasting disease is a horizontally transmissible disease that has been
reported to affect free ranging and captive deer, elk and moose populations in the
United States, Canada and South Korea (Sohn et al., 2002). After its first appearance in
Colorado in the 1960’s, the disease quickly expanded (Kuznetsova, et al., 2014).
Clinical symptoms include excessive thirst, behavioral alterations and progressive
weight loss followed by death in 2 weeks to 8 months (Williams, 1980). Although it is
not conclusively known how CWD is transmitted in the natural environment, it has been
shown that prion contaminated soil and plants can spread the infectious agent and cause
disease (Johnson et al., 2007; Pritzkow et al., 2015). CWD prions have been detected
saliva, urine and feces of CWD infected deer by either in vitro PrPSc detection assays or
in vivo infectivity bioassays (Haley et al., 2011; Henderson et al., 2015). Oral exposure
to contaminated material has been implicated as the most probable route for disease
transmission (Denkers, Telling, & Hoover, 2011).
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1.1.3 Bovine Spongiform encephalopathy (BSE)
BSE, also known as “mad cow disease”, was first reported in Great Britain in
the mid-1980’s where more than 1000 cases of neurological disorder in cows were
reported within a period of two years (Hope et al., 1988). It was suspected that the most
likely source of transmission in cattle was due to food-borne transmission (Parodi et al.
1990). This was later confirmed in 1996 when more than 160,000 cases of BSE were
reported in the Great Britain with most likely source of origin being contamination of
cattle’s supplementary feed with meat and bone meal (MBM) from scrapie infected
animals (Wilesmith et al. 1991; Anderson et al., 1996).

Since then, considerable

measures were taken that resulted in significant reduction in BSE cases in cattle (Budka
et al., 2008). BSE may manifest clinically as changes in behavior that may include
aggressiveness and motor impairment accompanied by weight loss. Even though BSE
was suspected to arise from scrapie-contaminated MBM fed to cattle, the infectious
agent responsible was found to be biochemically different than the one involved in
scrapie (Stack et al., 2002). Although there was a steady decline in BSE cases, a new
variant form of Creutzfeldt-Jakob diseases was identified in 1996 that raised suspicions
of disease acquired by consumption of meat that was contaminated with BSE infected
cow (Will et al. 1996). Later transmission studies along with immunochemical analysis
were able to confirm that the same agent involved in BSE in cows is also responsible
for vCJD in humans (Collinge et al. 1996; Bruce et al. 1997; Hill et al. 1997;
Weissmann & Aguzzi, 1997)
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1.2 Human Prion Diseases
1.2.1 Kuru
Kuru was one of the first human prion diseases that were shown to be
transmissible. This disease was first described by Gadjusek and Gibbs in 1959 in the
fore people of Papua, New Guinea (Gajdusek & Zigas, 1959).

The disease was

characterized by cerebellar ataxia accompanied by tremor, choreiform and athetoid
movements (Gajdusek & Zigas, 1959; Liberski P, 2012). It was believed to be spread
due to a cannibalistic ritual that involved consumption of infected brains from the
deceased. This was one of the first piece of evidence for oral transmission of prion
diseases in humans. Later, in a breakthrough study, three chimpanzees intra-cerebrally
challenged with brain extracts of kuru infected patients developed a disease similar to
the one seen in humans (Gadjusek, 1966).
1.2.2 Variant Creutzfeldt-Jakob disease (vCJD)
As mentioned previously, a novel form of human prion disease was reported in
the mid- nineties coinciding with the time BSE was epidemic in Great Britain (Will et
al.; 1996; Collinge J and Rossor, 1996). Variant CJD, also known as the human
equivalent of BSE, is of public health concern as its mode of transmission is foodborne.

Consumption of BSE-infected cattle meat was the most likely route for

transmission into humans (Ward et al., 2006) The incidence of vCJD has continued to
decline since the outbreak in mid-nineties due to the BSE related feed control policy
that was adopted by the United Kingdom (Will, 2003) but of concern now is the
secondary spread of the disease by iatrogenic transmission (blood transfusions,
7

contaminated surgical instruments) as the incubation period for CJD can span for
decades.

Clinical features involve sensory and psychiatric symptoms followed by

ataxia, cognitive impairment and involuntary movements (Zeidler et al., 1997).
Neuropathologically, along with the rest of prion disease pathology, PrPSc positive florid
amyloid plaques are present (Will, 2003). As vCJD is spread by consumption of
contaminated BSE infected meat, there is also considerable peripheral deposition of
PrPSc as found in skeletal muscle (Peden et al., 2006) and the lymphoreticular system
(Hilton et al., 2004).
1.2 Pathogenesis of prions after oral ingestion
Even though oral transmission for prion diseases has been known for a long
time, as shown by naturally or by deliberate inoculation of infectious agents (Maignien,
et. al., 1999) surprisingly very little work has been done to determine the immediate
fate of the infectious agent after ingestion. Previous studies have shown the localization
of infectious particles in Peyers’ patches of ileum and mesenteric lymph nodes (Aguzzi
2003; Bergstrom et. al 2006) followed by retrograde transport to the brain via peripheral
nerves. Presence of PrPSc in spleen and gut-associated lymphoid tissues (Andreoletti et
al., 2000) suggests that even after metabolic processing of PrPSc in the gastro-intestinal
track the infectious agent is not degraded and is transported across the intestinal barrier.
Many studies have been done showing trans-cellular transport of prions across the
intestinal epithelial barrier from the apical (mucosal) side to basolateral (serosal) side in
cell monolayers (Heppner et al., 2001; Mishra et al., 2004). Caco-2 cellular models for
intestinal barrier have shown that PrPSc can cross the barrier by endocytosis upon
interaction with the laminin receptor (Morel et al., 2005). On the other hand, it has also
8

been shown that M cells mediate transcytosis of prions across epithelial cell monolayers
(Heppner et al., 2001). In another study, Mishra et al. have shown that a prion-ferritin
complex is trans-cytosed in Caco-2 cell monolayers (Mishra et al., 2004). These studies
point out that after crossing the basolateral side PrPSc is immediately absorbed by
dendritic cells circulating in blood. Studies using infectivity and histological techniques
have shown that the circulatory system does not play a major role in PrPSc transport and
the infectious agent is directly taken up by the enteric nervous system (Maignien et al.,
1999; Kimberlin & Walker, 1989). Also, rapid appearance of infectious agent in submucosal lymphatics and not in Peyer’s patches of intestine has been shown in isolated
gut loops inoculated with prions (Jeffrey et al., 2006). These results suggest that most
likely once ingested prion protein can be transported by both peripheral nerves and/or
blood. However, most of these studies used methods and techniques that rely on
detection of prions after peripheral replication and not the original material
administered. It is important to note that neither conventional histology nor infectivity
studies have the sensitivity to detect the immediate transport of PrPSc within minutes or
hours after oral exposure. One breakthrough technique for detection of prions that has
led to substantial advances in the past decade is the Protein Misfolding Cyclic
Amplification technology (PMCA).

PMCA technology effectively enables prion

replication even from a single oligomeric particle of PrPSc (Saborio, Permanne, & Soto;
2001; Saá et al., 2006). Unlike conventional techniques, the great sensitivity achieved
from this technique to amplify otherwise undetectable amounts of PrPSc has allowed for
detection of prions in various bodily fluids at both pre-symptomatic and postsymptomatic stages of the disease (Saa, P., 2006; Chen, Morales, Barria, & Soto, 2010;
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Moda et al., 2014). In addition, by using this technique it has been recently reported
that inoculated prions can be detected at short times after intraperitoneal administration
in experimental hamsters (Chen et al., 2014). The schematics involved in the PMCA
technique are shown in Figure 2 and expanded in the Methods section. A detailed
study to determine the distribution and metabolism of PrPSc immediately after oral
ingestion can provide key evidence to determine the bioavailability of prions and
development of therapeutic strategies.

Figure 2: Schematic diagram for protein misfolding cyclic amplification. PMCA is based on
the assumption that prion replication occurs by a seeding/nucleation model (Caughey, 2003),
Sc
C
in which PrP seeds bind and misfold PrP by incorporating the protein into the polymer. In
Sc
C
C
PMCA, PrP and PrP are mixed and incubated, allowing the misfolding of PrP , which
Sc
permits the incorporation and growth of PrP aggregates. After incubation, samples are
Sc
submitted to sonication in order to fragment PrP polymers, thereby generating new free ends
suitable for continued prion replication. This process is cyclically repeated in order to produce
C
an exponential amplification of PrP conversion (Morales, et al., 2012) (figure with legend
reproduced with permission from Nature Publishing Group).
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Hypothesis

Our hypothesis is that infectious prions resist gastrointestinal metabolism and directly
cross the intestinal barrier after per oral administration, distributing in blood and various
organs.

In order to test this hypothesis, we will address following two aims:

characterization of the metabolic profile of prions in gastrointestinal tract tissues by in
vitro experiments and determination of the initial distribution of infectious material
within hours of ingestion in vivo.

11

CHAPTER 2
Materials and Methods
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Materials and Methods
Ethics statement
All animal experiments were approved by and conducted in strict accordance
with guidelines of the Animal Care and Use Committee of the University of Texas
Health Science Center in Houston and complied with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health.
2.1 Production of prion proteins in host animals:
2.1.1. Animal infection with Rocky Mountain Laboratories (RML) scrapie prions
The Inoculum for the infection study was prepared as follows;
Two mouse brains infected with RML prion strain were homogenized in 10mL
Dounce homogenizer. A 10% homogenate was prepared in 1x PBS with protease
inhibitor. The homogenate was spun down at 2000xg for 5 minutes. The supernatant
was collected for inoculation in mice and debris was discarded.
2.1.1. Animal inoculation with RML prions
Twenty five female 129S2 mice at the age of 3-4weeks were purchased from
Harlan laboratories (Houston, Texas). Mice were divided in groups of five in each cage
and ears were punched for identification. They were housed in light and temperature
controlled mouse prion room with 12 hours of light and dark cycles and free access to
water and food. Each mouse was inoculated intraperitonealy with 100 µL of RML
inoculum. After inoculation, mice were inspected daily for signs of prion disease. At
seven months, the symptoms for early clinical stage of scrapie including piloerection,
hunched posture and ungroomed appearance, were observed. At the terminal stages of
disease which were defined by clinical signs of unsteady gate, ataxia, and limb
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paralysis, mice showed 20% of body weight loss or complete paralyses were sacrificed.
The brain was harvested from each mouse and frozen at -80°C for purification
experiments.
2.2 Purification of PrPSc
Purification of PrPSc from the infected brain was performed as described
previously (Hetz et al., 2003) with modifications. A 10% brain homogenate (w/v) was
prepared in 1xPBS with 20% Sarkosyl to precipitate prion proteins. The mixture was
thoroughly sonicated using a probe sonicator (Bandelin Sonoplus) at power of 45%
until it became clear. Then, the mixture was then centrifuged for 15 min at 5311 x g at
4°C (Beckman Coulter Allegra 25R). To the supernatant, 1/3 volume of 1X
PBS/0.1%SB3-14 was added and ultra-centrifuged using T 70.1 rotor at 198,000 x g for
2h at 20°C (Beckman Coulter Optima XE-90 Ultracentrifuge). The resulting pellet was
reconstituted with 1 ml of 1xPBS/10%NaCl/0/1%SB3-14, and sonicated until clear
solution was obtained. One mL of the mixture was layered over 3 mL of 20% sucrose
cushion made in 1x PBS/10% NaCl/0.1% SB3-14.

This material was then ultra-

centrifuged at 257,000 x g for 3h at 4°C using T 70.1 rotor. The pellet was dissolved in
1mL of 1xPBS/0.1%SB3-14 and extensively sonicated until the solution became clear.
Then Proteinase K (PK) (Sigma-Aldrich) was added at the final concentration of
100µg/mL and the mixture incubated at 37°C for 2 h (Eppendorf Thermomixer R). The
PK digestion process was stopped by adding 1mM of Pefabloc SC (Roche). Next, this
material was sonicated and centrifugation with sucrose gradient for 1.5 h repeated. The
final pellet was re-suspended in 300µL of sodium phosphate buffer (pH 7.4).
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The preparation was labeled as purified PrPSc. Western blot and silver staining was
performed with the purified PrPSc to confirm the purity of the material.

The

concentration of PrPSc was determined by micro BCA protein assay kit (Pierce).
2.3 Western blot of Purified PrPSc
Ten µL of purified PrPSc was dissolved in 1x sample buffer with 1mM DTT
(Life Technology Inc. LDS sample buffer), the mixture heated for 10 min at 100°C,
briefly spun down and loaded on 12% NuPage Bis-Tris gel (Life Technologies Inc).
Also, 3µL of protein ladder (Fisher BioReagents™ EZ-Run™ Pre-Stained Rec Protein
ladder) was loaded. The gel was run for 20 min at 70V and 1.5 h at 135V with 1x MES
SDS running buffer (NuPage). After SDS-PAGE, the proteins were transferred at
constant current of 0.8A at 4°C to a nitrocellulose membrane (GE Healthcare
Amersham™ Protran™ premium 0.45µm NC) for 1 h. The membrane was blocked for
to prevent unspecific protein binding by treating with 2% milk in PBST 0.05% for 1 h
at room temperature. Following blocking, the membrane was incubated with 6D11
monoclonal antibody (Covance) diluted at 1:2500 at 4°C overnight on shaker. Next
day, the membrane was washed for 10 min three times in washing buffer at room
temperature. Thereafter, the membrane was placed in washing buffer containing antimouse IgG Secondary antibody (Sigma Aldrich anti-mouse IgG) diluted at 1:3000, and
incubated at room temperature for 1hr with gentle shaking followed by three 10 min
washes with PBST 0.05%. The membrane was developed using ECL prime kit (GE
Healthcare Amersham ECL prime western blotting).
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2.4 Silver Staining of PrPSc
Following gel electrophoresis, silver staining was carried out using silver
staining kit (Invitrogen SilverXpress silver staining kit). All steps were performed
according to the instruction from the manufacturer.
2.5 Radiolabeling of purified PrPSc
Radiolabeling of purified PrPSc was performed by chloramine-T method with
[125I]Na (Perkin-Elmer), as described in previous reports (Gitlin et al., 1958 ; Urayama
et al,. 2004). Purified PrPSc (10 µg) was mixed with [125I] Na (2 mCi) in 250 mM
chloride-free sodium phosphate buffer (pH 7.4), and the protein labeling was initiated
by adding chloramine-T (10 µg/reaction) into the mixture. After 1 min, the reaction
was terminated by adding sodium metabisulfite (100 µg/ reaction). Each labeled agent
was purified by Sephadex G-10 chromatography to remove free iodine. The labeled
PrPSc was diluted with phosphate buffered saline and further centrifuged in albumin precoated Microcon filtration tube (Mw cutoff: 10 kDa) at 12,000 rpm for 30 min to further
remove free iodine from the G-10 eluate. Labeled PrPSc was extensively washed by this
procedure. Radioactivity was measured after each wash (Cobra II gamma counter,
Packard).

The radioactively labeled PrPSc preparations we used had > 90%

precipitation with trichloroacetic acid (TCA) (Sigma).
2.6 Preparation of tissue homogenates for in vitro metabolism study
Female 129S2 mice at 8-10 weeks of age were fasted for 16 h prior to being
sacrificed for gastro-intestinal tissue collection. Following tissues were obtained for
homogenate preparation, stomach, duodenum, jejunum, ileum and colon. Ten % (w/v)
tissue homogenate in saline were freshly prepared on ice each time of experiment
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(prepared in a Precellys 24 device). Each homogenates was spun for 5 min at 3000 x g
at 4°C (Beckman Coulter Allegra 25R). The supernatant was saved for the study.
2.7 Tissue metabolism of 125I-PrPSc
Metabolic profiling of

125

I-PrPSc was investigated by following procedure.

Tissue homogenate (1mL) was incubated with 125I-PrPSc (3 x 105 cpm) for 1, 3 and 6h at
37°C on a thermomixer (Eppendorf Thermomixer R) shaking at 600rpm.

Three

hundred µL aliquot was sampled at designated time points, and the sample frozen in
liquid nitrogen for HPLC analysis at later time. Saline was also incubated with

125

I-

PrPSc for control experiments.
2.8 Size-exclusion HPLC experiments
The stability of 125I-PrPSc in stomach, duodenum, jejunum, and ileum and colon
homogenates was examined using HPLC with a size exclusion column. HPLC system
used for this study consisted from Shimadzu UFLC system LC-20AB and the size
exclusion column BioSep-SEC-S4000 (7.8 mm × 300 mm, Phenomenex, CA). The
mobile phase consisted of 25 mM sodium phosphate buffer (pH 7.4) Tissue sample was
centrifuged at 12,000 x g for 10 min (Eppendorf Centrifuge 5415D). The supernatant
(300µL) was separated and loaded onto HPLC column. Fractions were collected at
1mL/min interval for first five min followed by 10-second intervals for 5-15 min at a
flow rate of 1.0 mL/min, and the radioactivity in each fraction was detected using a
gamma counter. TCA precipitation of each fraction was also performed. Molecular
weight markers, including thyroglobulin (669kDa), aldolase (158kDa), conalbumin
(75kDA), carbonic anhydrase (29kDa) and aptotinin (6.7kDa) (GE Healthcare Gel
Filteration Calibration kit HMW) were employed to estimate the relationship between
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the size and retention time A single peak for each marker was confirmed and the peak
time defined as the retention time. In addition, the retention time of Iodine-125 was
measured.
2.9 Data analysis and statistical analysis
The radioactivity normalized by % of injected amount in each eluate from sizeexclusion chromatography was plotted against retention time. The areas under the
curve (AUC) values were calculated from the fractions between 6.0 and 10.0 min,
which represents intact

125

I-PrPSc. The radioactivity below 3 times of the background

level (70 cpm) was excluded from the analysis which was seen after 11.0 min.
TCA precipitation was performed to estimate the levels of intact 125I-PrPSc.
For TCA precipitation, following was done:
In each HPLC fraction 100µL of 1% BSA (Sigma Aldrich) prepared in DI water
was added followed by ice cold 500µL of 30% TCA (Sigma Aldrich) prepared in DI
water. This mixture was then centrifuged for 15 min at 4000 x g at 4˚C. The supernatant
and pellet was separated and the radioactivity in each was measured.
The radioactivity in each pellet and supernatant and % of radiolabeled protein was
calculated by the following formula:
TCA%= cpm in pellet/ (cpm in pellet+cpm in supernatant)*100
2.10 Statistics analysis
Statistical comparison was performed by one-way ANOVA followed by
Dunnet’s multiple comparison test against percent area under the curve (%AUC) from
the pre incubated input 125I-PrPSc.
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Methods and materials for distribution of PrPSc in vivo after oral ingestion
2.11 Inoculum preparation
Two symptomatic (RML prion strain) infected mice were sacrificed by CO2
inhalation and brains were harvested. Ten percent homogenate (w/v) was prepared in
PBS supplemented with a cocktail of protease inhibitor (Roche Diagnostics). The
homogenate was further processed as described previously (Morales et al., 2012). The
homogenate was briefly centrifuged at 800 x g for 1 min at 4°C (Beckman Coulter
Allegra 25R).

The supernatant was collected and incubated with 20% sarkosyl

(prepared in PBS) for 15 min at room temperature on rotator. The resulting sample was
then ultra-centrifuged using T70.1 rotor at 100,000 x g for 1 h at 4°C (Beckman Coulter
Optima XE-90 Ultracentrifuge). Supernatant was discarded and two volumes of 1x
PBS + PI were added and ultra-centrifuged again at 100,000 x g for 30 min at 4°C. The
final pellet was re-suspended and sonicated in one volume of PBS + PI and frozen at 20°C for Western blot analysis and animal inoculations.

2.12 Oral inoculation of PrPSc in mice
Three female mice 129S2 aged at 8-10 weeks were fasted for 16 h prior to
inoculation. Each animal was given 500 µL of inoculum and culled after two hours.
Blood (heparinized, 12.5 mg/mL), brain, spleen, liver, colon, intestines and stomach
were collected. Extreme precaution was taken while tissue collection to prevent cross
contamination.

Surgical instruments, decontaminated by immersion in 2N NaOH

solution for 24hrs, were used for organ collection. Each tissue had separate sets of
surgical instruments. The blood after ficol (GE Healthcare) was then separated into
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plasma, buffy coat and red cells as suggested by the manufacturer (GE ficol paque).
Each tissue sample was frozen in -80°C for PMCA experiments.
2.13 Tissue homogenates preparation for PMCA
Forty percent tissue homogenates were prepared as described above and treated
with 20% sarkosyl prepared in PBS and ultra-centrifuged as explained in section 2.11.
The final pellet was re-suspended in 100µL of PMCA substrate (mouse) prepared in
conversion buffer as previously described (Morales et al., 2012) and later on in this
section.
2.14 Blood components processing
The plasma and buffy coat collected (400µL) was mixed with equal volumes of
PBS + PI and ultra-centrifuged at 100,000 x g and 4°C for 1h. Two volumes PBS + PI
were added to resulting pellets and ultra-centrifuged in the same conditions mentioned
above for additional 30mins. Final pellets were re-suspended in PMCA substrate.
2.15 Protein Misfolding Cyclic Amplification
The PMCA protocol was carried out as reported previously (Morales et al.,
2012).

PMCA substrate (wild-type mouse brain homogenate) was prepared as

described previously (Morales et al., 2012).

129S2 mice were sacrificed by CO2

inhalation and brains were collected following perfusion with PBS + 5mM EDTA.
Immediately after harvesting, the tissue was frozen in liquid nitrogen and stored in 80°C. PMCA substrate preparation was done as following: 10% brain homogenate
(w/v) was prepared in conversion buffer (150mM NaCl, 1% Triton X-100 in 1X PBS)
with PI. Tissue pellets that were re-suspended in PMCA substrate were submitted to
PMCA (Morales et al., 2012). The PMCA was carried out in an automatic horn
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sonicator (Qsonica). Samples (in individually capped 0.2 mL PCR tubes) were placed
in PMCA tube holder placed on an automatic horn sonicator (Qsonica) filled with water
at 37°C and submitted to 240 PMCA cycles for first round followed by two rounds of
96 cycles. Each cycles consisted of 29 min and 40 sec of incubation in water bath at
37˚C followed by 20 second of sonication at Amplitude 30 and power between 260300W. At the end of each round serial dilutions were made by diluting 10µL of the
resulting material into 90µL of fresh PMCA substrate. These new mixtures were
subjected to additional PMCA rounds to increase amplification efficiency. After each
round, 19 µL of sample were saved for Western blot analysis.
2.16 Western blotting of PMCA amplified material
Samples saved from each PMCA round were treated with 50µg/mL PK and
incubated for 1 h at 37°C with shaking. PK reaction was stopped by addition of sample
buffer supplemented with 1mM DTT and heated for 10 minutes at 100°C. Western
blots were then done on each sample as described above in 2.3.
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CHAPTER 3
Results
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3.1 Purification and radiolabeling of PrPSc from infected

brain, and

characterization of size-exclusion HPLC chromatography
Figure 3 shows immunoreactivity and protein purity of purified PrPSc of RML
prion strain obtained through experimental procedure (Section 2.2). The presence of
PrPSc in SDS-PAGE and subsequent western blotting was confirmed by silver staining
in gels and specific immunoreactivity probed by 6D11 monoclonal antibody. PrPSc
bands were ranged within the molecular weights between 27kDa and 30kDa as reported
previously (Bendheim et al., 2015). After PK digestion the electrophoretic mobility of
PrPSc (Figure 3) shows a majority of monoglycosylated isoform of prion protein and
size of about 21kDa for the unglycosylated band (Morales et al., 2007).
The purity was confirmed by silver staining in which protein derived bands other than
PrPSc were not observed. Silver staining and western blotting of PrPSc were conducted
each time when purification of PrPSc from infected brain was performed, and results
were reproducible.
Radiolabeling of PrPSc was performed with these preparations. Tricholoacetic acid
assay showed >90 percent of purified PrPSc protein being successfully labeled with 125I.
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The size distribution of

125

I-PrPSc based on molecular weight was analyzed by size-

exclusion radio-HPLC
HPLC chromatography (Figure 4A). The HPLC eluate was reserved
for TCA precipitation to estimate intactness of

125

I-PrPSc. In addition,, the retention

times in size-exclusion column were characterized with high molecular weight markers
(Table 1), For markers the retention times were; 7.35 minutes for thyroglobulin
(669kDa), 9.45 minutes for aldolase (158kDa), 10.0 minutes for conalbumin (75kDa),
10.8 minutes for carbonic anhydrase (29kDa) and 12.0 minutes for aprotinin (6.5kDa).
Also, the retention time for iiodine-125 was 12.3 minutes (Fig 4B).
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125

I-PrPSc (1x105 cpm) (now will be referred to as input 125I-PrPSc) was injected onto the

column and fractions were collected at the flowrate of 1mL/min from 1-5 min at 1 min
interval and from 5-13 min at 10 sec intervals.
The radio chromatogram of input 125I-PrPSc (1x105 cpm) is shown (Figure 4A).

125

I-

PrPSc was injected onto the column and fractions were collected at the flowrate of
1mL/min from 1-5 min at 1 min interval and from 5-13 min at 10 secs intervals. On xaxis is time in min and right y-axis is raw cpm (blue) and TCA normalized cpm (red)
(Figure 4A). On right y-axis is percent of injected dose/mL (%ID/mL) plotted (Figure
4A). The chromatogram of

125

I-PrPSc spans between 6.0 -10.0 min showing various

sizes ranging from 669 to 29 kDa (Figure 4A). Separately, iodine-125 was
characterized in the column showing a retention time at 12.3min (Figure 4B).

25

A.

B.

Figure 4. Radio-HPLC chromatogram of 125I-PrPSc with molecular weight
markers is shown. The area under the curve was analyzed for 6.0 -10.0
minutes as shown by red line under x-axis (A)
Retention time of iodine
iodine-125 was 12.3 minutes (B)
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Protein

Molecular Weight (Da)

Retention time (minutes)

Thyroglobulin

669,000

7.35

Aldolase

158,000

9.45

Conalbumin

75,000

10.00

Carbonic anhydrase

29,000

10.80

Aprotinin

6,500

12.00

Table 1. High molecular weight markers retention times in Phenomenex Bio sep sec
s4000 size exclusion column

3.2 Characterization of metabolic pattern of radioactively-labeled, PrPSc by
trichloroacetic acid precipitation assay (TCA) and high-performance liquid
chromatography (HPLC ) in vitro
Next, freshly prepared tissue homogenates (stomach, duodenum, jejunum,
ileum, and colon) were incubated with

125

I-PrPSc (3x105 cpm) for 1, 3 and 6 h and

analyzed by radio-HPLC chromatography (Figure 5). The %ID/mL of tissues was
plotted with input

125

I-PrPSc (Figure 5). As a processing control,

125

I-PrPSc was also

incubated with saline. The radio-chromatogram of saline shows minimal changes in
125

I-PrPSc after 1hr (Figure 5A). The radio chromatogram of stomach, colon, and saline

control (Figure 5B, 5F and 5A) shows the major peaks between 6.0-10.0 min which
was similar to the input

125

I-PrPSc. In contrast, the duodenum (Figure 5C) , jejunum

(Figure 5D) and Ileum ( Figure 5E) showed decrease in intact protein of
compared to input

125

125

I-PrPSc

I-PrPSc, indicating that the amount of intact125I-PrPSc was reduced

in duodenum, jejunum and ileum tissue 1h after incubation. In addition to 1 h, for each
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tissue homogenate samples collected at 3 h and 6 h were also injected in HPLC column
and chromatograms were analyzed. Results were similar to the 1hr time point (Figures
6 and 7).
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Figure 5. Radio HPLC-Chromatogram of tissue homogenates incubated with ISc
PrP at 1hr. Saline only (A) , Stomach (B), Duodenum (C) , Jejunum (D), Ileum(E)
125
Sc
and Colon(F) %Injected dose per mL (%ID/mL) of input I- PrP (red) and
%Injected dose per mL (%ID/mL)of tissue homogenates (green). The red line on xaxis of each graph marks the time (6.0-10.0min) measured for calculating total area
under the curve.
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Figure 6. Radio-HPLC Chromatogram of tissue homogenates incubated with ISc
PrP at 3hr. Saline only (A), Stomach (B), Duodenum (C), Jejunum (D), Ileum (E)
125
Sc
and Colon (F) %Injected dose per mL (%ID/mL) of input I-PrP (red) and
%Injected dose per mL (%ID/mL)of tissue homogenates (blue). The red line on xaxis of each graph marks the time (6.0-10.0min) measured for calculating total area
under the curve
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Sc

Figure 7. Radio-HPLC Chromatogram of tissue homogenates incubated with I- PrP at 6hr.
Saline only (A), Stomach (B), Duodenum (C), Jejunum (D), Ileum (E) and Colon (F)
125
Sc
%Injected dose per mL (%ID/mL) of input I-PrP (red) and %Injected dose per mL (%ID/mL)
of tissue homogenates (purple). The red line on x-axis of each graph marks the time (6.0-10.0
min) measured for calculating total area under the curve
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Table 2: %AUC in tissues is based on the AUC value compared to the input 125I-PrPSc as 100 ± 20.7%
Time in Hours
1
3
6

Stomach
70.2 ± 16.2
64.3 ± 11.2
79.0 ± 14.2

Duodenum
36.3 ± 7.2
29.3 ± 7.2
28.5 ± 9.1

Jejunum
37.4 ± 7.1
35.2 ± 8.1
31.0 ± 11.2

Ileum
56.2 ± 9.2
42.3 ± 5.7
42.1 ± 7.7

Colon
64.4 ± 16.5
56.4 ± 19.3
56.3 ± 22.1

Saline only
60.4 ± 11.7
64.0 ± 9.5
67.5 ± 14.3

Mean ± SEM (n=3) are reported

The in vitro metabolite study to measure intactness of PrPSc in gastro-intestinal tissue
homogenates at various time points was repeated by performing three separate
experiments. The mean and SEM of % area under the curve (AUC) (measured between
6.0-10.0 min) for all tissues at different time points is shown (Table 2).
In table 2 the mean of %AUC (6.0-10min) along with its respective SEM is listed for
each tissue. As seen by table 2 the change is metabolic profile for duodenum, jejunum
and ileum is time-dependent and compared to input

125

Sc

I-PrP . The amount of reduction

seen in graph duodenum, jejunum and ileum homogenates (Figure 8) are less than 50%
as compared to the input 125I-PrPSc.
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Figure 8. Figure 8. Gastrointestinal (GI) metabolite profile of I-PrP after
incubation with 10% mouse tissue homogenates. (A) The metabolic profile of
stomach, duodenum and jejunum. (B) The metabolic profile of ileum, colon and saline
only control. Each time point represents the mean value and standard error of the
mean. All measurements were done in triplicates. Comparison of total area under the
125
Sc
curve (6.0 – 10 min) of tissue homogenates incubated with I- PrP all time points
125
Sc
against input material ( I- PrP ) as 100% ± 20.7
Statistical comparison was performed using one-way ANOVA followed by Dunnet’s
multiple comparison tests
*p <0.05, **p<0.01
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Summary

In-vitro metabolic profile of prions in gastro-intestinal tissues
Detailed analysis of metabolic profile of

125

I-PrPSc in gastro-intestinal tissues

showed the amount of reduction in intact 125I-PrPSc with time. The significant reduction
is seen in the duodenum, jejunum and ileum, which is mediated through endogenous
protease activity.
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3.3 Detection of self-propagating prions in blood and tissues after per-oral
inoculation using the protein misfolding cyclic amplification (PMCA) technology
As a preliminary approach to bio-distribution studies, we designed and
performed experiments aimed to quantitatively detect self-replicating prions in blood
and tissues of mice orally challenged with misfolded PrP. To study the immediate
distribution of PrPSc in vivo, first we prepared a homogeneous inoculum suitable for our
purpose (i.e. free from tissue debris). The material to inject in mice was prepared by
mixing one volume of 10% BH and one volume of a 20% sarkosyl solution in order to
disrupt membranes and isolate protein aggregates from unspecific bound molecules.
After 15 min incubation at RT gently shaking, samples were ultra-centrifuged.
Resulting pellets were washed and finally re-suspended in saline buffer using extensive
sonication (see chapter 2). Western blots of 10% RML brain homogenate before and
after treatment are shown in Figure 9. As seen in the figure, this treatment resulted in a
minimal loss of PrPSc, data consistent with previously published results (Morales et al.,
2008).

Next, this inoculum was subjected to PMCA (see chapter 2 methods and

materials) to set in vitro amplification conditions for this specific inoculum (Figure 10).
Three PMCA rounds were done 48 h each round (see Chapter 2 for details). The initial
samples, labeled as frozen (not submitted to PMCA) are shown (Figure 10A). As
expected, they do not show positive signal in the Western blot due to their high dilution.
After first round, 10-5 dilution of inoculum was detected (Figure 10B). Following
PMCA rounds revealed presence of misfolded prions in 10-10 brain dilution (Figure
10C and Figure 10D). Also two negative controls containing 10% normal mouse brain
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homogenate
te only were added to the PMCA reaction to control for inter-tube
inter
contamination. As expected, results were negative confirming true PrPSc detection.
Bioassays were performed by injecting 500µL of this inoculum per orally in three wild
type mice to study short-term
term distribution in various tissues.

A.

B.

Figure 9. Western blot of 10% PrPSc (RML) brain homogenate
dilutions (A). Western blot of 10% PrPSc (RML) brain
homogenate dilutions after sarkosyl treatment (B).
). All samples
were treated with PK 50µg/mL, 1 h at 37°C, shaking at 600rpm.
First lane on both A and B is 10% normal mouse brain
homogenate without PK treatment for reference.
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A.

B.

C.

D.

Figure 10. Western blot of “sarkosyl cleared” inoculum after PMCA. Dilutions of inoculum in normal
brain substrate (A) not submitted to the PMCA reaction (frozen). PMCA amplification after first,
second and third rounds (B - D).
). Labelled in red is the negative control on each gel
g (A-D).x means no
sample in that lane (B).
Prior to inoculation, mice were fasted for 16h with free access to water in order to clean
the gastro-intestinal
intestinal tract from fecal material. Two hours after per oral administration
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of prion containing material, the three mice were culled and blood, brain, spleen, liver,
colon, intestines and stomach were collected respectively. For each tissue, either 10%
(stomach, intestines, colon, liver, spleen, brain) or 40% homogenates (stomach,
intestines, colon, liver, spleen, brain) (w/v) were prepared in PBS supplemented with PI
and subjected to PMCA (see Chapter 2 for details). Before PMCA, Western blots were
performed on 10% tissue homogenates (w/v) in order to assess for direct visualization
of PrPSc by this method. As expected, none of the tissues analyzed showed positive
signal for PrPSc, indicating that the concentration in each tissue was below the detection
limit of conventional techniques (Figure 11).

Signals seen in the Western blots

corresponded to unspecific bands as tested by incubating and developing the blot
membranes with secondary antibody only. These non-specific bands are expected to be
a consequence of blood components (data not shown).
After PMCA, positive signal was detected in plasma (3/3 animals), brain (3/3 animals
and intestines (1/3 animal) (Figure 12). These results show that self-replicating prions
can directly cross the intestinal barrier and target different organs.

The effective

detection of PrPSc in brain and no other tissues is suspected to be a consequence of the
PMCA conditions which has been standardized for this specific tissue. As seen, all
negative controls (substrate only) in the PMCA stayed negative s suggesting absence of
false positive signals in our specimens (Figure 12).
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Figure 11. Western blot of 10% mouse tissue homogenates (before
PMCA) taken two hours after per oral inoculation with sarkosyl
treated PrPSc (RML) (A and B) ST: Stomach, IN: Intestines, CO:
Colon, LI: Liver, SP: Spleen, BR: Brain
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Figure 12. Western blot of tissue homogenates after PMCA amplification
All samples are treated with PK 50µg/mL, 1h 37
37˚C
˚C at 600rpm before gel
electrophoresis. Three rounds done first round was five days followed by 48hrs round
each. 50µL of 40% Tissue homogenate cconcentrated.
oncentrated. Blood equivalent to 400µL of
whole blood used (A). Negative controls with just normal brain homogenate (B)
(
ST: Stomach, IN: Intestines, CO: Colon, LI: Liver, SP: Spleen, BR: Brain, PL: Plasma
and BC: Buffy coat
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Summary
Initial distribution of infectious material within hours of ingestion in vivo
In this section, we were able to partially purify the prion protein from terminally
infected mice brains, prepare the inoculum from it and successfully inoculate animals
via oral ingestion. Two hours after, animals were culled and various tissues, including
blood, were collected and subjected to various rounds of PMCA. Our results show the
efficient detection of self- propagating prions in plasma for all three animals inoculated
(Figure 12). Also, positive signal was seen in intestines (1/3) and brain (3/3) animals.
These results signify that within extremely short time after ingestion of prions the selfpropagating agents can spread through the gastrointestinal barrier and be taken up by
blood.
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CHAPTER 4
Discussion
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4.1 Characterization of metabolic pattern of radioactively-labeled PrPSc
The gastro-intestinal tract serves as an important barrier as well as interface for
the materials orally ingested. Much work has been done to study the transport of PrPSc
from gut to brain (Kimberlin et.al. 1989; Beekes et.al. 2000; Andreoletti et al. 2000,
Shmakov et.al.2001; Bergström et al. 2006; Kujala et al. 2011). Surprisingly, very little
is known about the metabolic profile of prions at short times after ingestion. Most of
the methods used previously to determine this were not sensitive enough to detect the
smallest changes in the size distribution of the PrPSc aggregate after digestion.
Knowing this information can be vital in determining the mechanism and initial fate of
the infectious agent and its bioavailability in vivo. In order to study PrPSc metabolism it
is important to have a detailed and quantitative in vitro characterization of PrPSc
stability in gastrointestinal tissue homogenates. This information can provide data
about the maximal capability of each tissue to metabolize PrPSc. In this aim, we
investigated PrPSc metabolism in various gastrointestinal tissues homogenates at
different time points. To achieve this, the first step was to have a pure and efficient
preparation of PrPSc. Various purification protocols have been reported that yield a
variable degree of PrPSc purity. In our studies we modified previous methods to obtain
an extremely pure preparation of PrPSc from infected mouse brain homogenates (Figure
3). This is in agreement to a study that was just recently published showing purity of
PrPSc comparable to that obtained in our preparations (Wenborn et al. 2015). Freshly
prepared stomach, duodenum, jejunum, ileum and colon homogenates were separately
incubated with biologically active radioactively labeled PrPSc. Samples were collected
at 1, 3 and 6 hours and analyzed by HPLC to determine the degradation profile of the
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radiolabeled protein. The difference in the profile of the radio-HPLC chromatogram of
125

I-PrPSc (input

125

I-PrPSc) was compared to the profile after incubation with GI tract

tissue homogenates. Radiolysis and intactness was measured by TCA precipitation
analysis coupled to HPLC characterization. Our results show for the first time that
purified

125

I-PrPSc incubated in duodenum, jejunum and ileum homogenates undergoes

a significant degradation (more than 50%) which could be due to endogenous proteases
present in the freshly prepared tissue homogenates. This is in contrast to other tissue
homogenates from the GI track, such as stomach and colon in which levels of 125I-PrPSc
underwent minimal reduction. It has been shown that the most probable site for PrPSc
uptake after oral exposures are the intestinal lymphoid follicles (Payer’s patches)
(Beekes & McBride, 2000). Previous work has been done with gut loops from wild
type sheep investigating the digestion of PrPSc in distal jejunum and ileum components
at short time points ranging from 15 to 120min. Their results showed that PrPSc signal
reduction is observed in both in vitro and in vivo intestinal environment (Dagleish et al.
2010). Studies done for 48 hours have shown almost complete degradation of 125I-PrPSc
incubated in a cocktail of alimentary track fluids (Jeffrey et al. 2006). However, these
studies have just examined the digestion of PrPSc in distal jejunum and ileum and not in
the duodenum and proximal jejunum. Also, these studies did not analyze a detailed
profile of PrPSc degradation and unlike our highly sensitive experiments using
radiolabeled PrPSc used less sensitive techniques like western blot for detection. Our
results show that purified PrPSc appears as a broad peak with an estimated molecular
weight of 310kDa, indicating of a small oligomer (8-10 monomers of PrP). After
incubation with duodenum and jejunum extracts (Figure 8) this oligomer is rapidly
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degraded. It has been shown previously that minimum infectious unit of PrPSc is a
trimer of PrPSc (Groth, 1988), but the predominant species appear as large molecular
weight fibrils and intermediate size oligomer in the range of what we observed in the
present study. It is likely that large fibrillar aggregates of PrPSc were removed during
the purification or the radio-labeling procedure. Nevertheless, it has been shown that
the most infectious prion particles are oligomers of around 500KDa molecular weight
(Silveira, 2005). In the light of our finding it would be interesting to investigate further
the exact role of duodenal and jejunum in uptake and transport of prions from GI tract
to the brain in vivo.

Detection of self-propagating prions in tissues after per-oral inoculation
The most natural route for prion transmission is by ingestion of contaminated
materials. Previous results from our lab showed that prions intra-peritonealy injected in
hamsters were detected in brains and spleens by PMCA within few days after
inoculation, although at sub infectious levels (Chen et. al., 2014). Here, we investigated
the initial uptake of prions in blood at shorter time points after oral challenge which is
probably the most natural route for transmission of prion diseases.

Much of the

previous work has been done by infectivity bioassay to detect prions after long times
after administration. Moreover, most of the techniques used for detection in these
studies were not sensitive enough to detect minute quantities of prions within hours in
various tissues in vivo. Here we showed that by employing the PMCA technology we
can detect the tiny quantities of self-propagating prions in different biological samples
after oral injection. Three mice were inoculated with RML prions (an established
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mouse prion strain) and sacrificed after 2 h. The content of infectious prions in several
organs related to prion uptake and transport were measured by PMCA (Figure 12).
Positive signals for PrPSc were detected in plasma of all animals orally inoculated with
prions. Previous work has shown that infectious agent can reach the brain from blood
because of vascular deposition of PrPSc seen in the basement membrane of endothelial
cells of hypothalamus (Sílvia Sisó, González, & Jeffrey, 2010). Also, deposition of
PrPSc in circumventricular organs in sheep was always observed regardless of the route
of challenge suggesting that PrPSc can reach the brain by blood transport (S. Sisó,
Jeffrey, & González, 2009). In agreement with a recent study (Elder et al. 2015), our
results show that prions orally ingested can cross the gastro-intestinal barrier and be
taken up in blood within just two hours after inoculation. Importantly, PrPSc found in
blood and organs was intact and retained the capacity of self-propagating in a PMCA
reaction (Figure 12). Also, this is the first time self-propagating prions have been
detected in brain after oral inoculation suggesting a direct transport of inoculated prions
without peripheral replication. This information can be vital in understanding the
pathway followed by prions immediately after ingestion and quantifying the amount
taken up by various tissues.

Also, work in this regard can help develop early

interventional therapies and diagnostic tests for prion diseases.
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CHAPTER 5
Conclusions and Future Directions

47

Conclusions and future work
In conclusion, as part of this work we have shown two findings that were not
known previously in the field of prion diseases. First, our metabolic profiles of prions
in gastrointestinal tract show that duodenum, jejunum and ileum have the capacity to
degrade PrPSc. For future, it would be necessary to study this in an in vivo setting to
map a distribution and degradation profile of orally ingested prions. Secondly, we have
shown that following oral ingestion of prions the self-propagating agent reaches the
blood and brain within just two hours. Future work in this regard can involve a detailed
quantitative study including more time points and tissues. Also, it would be important
to study the mechanisms responsible for PrPSc transport at the intestinal barrier and the
subsequent distribution from blood to various tissues especially brain and what role
does this play in the pathogenesis of the disease.
The above study also lays some of the groundwork to obtain a detailed knowledge of
how prions are taken up, distributed, metabolized and cleared from the body which can
provide an estimation of tissue risks and development of therapeutic strategies. More
than likely in natural infection of prions the quantity of the infectious agent an organism
is exposed to is very low, thus it is imperative to know the quantity and mechanism of
the amount of the infectious agent is absorbed, metabolized, distributed and cleared in
the body. The initial fate of the infectious agent could play a vital role in determining
how the disease would manifest and progress with time.
The findings generated by bio-distribution and in vivo metabolite profiling can open
novel avenues to develop therapeutic strategies aiming to prevent prions to get into the
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brain or increasing prion elimination by enhancing metabolism. Also, our finding that
self-propagating prions can reach blood and brain within two hours of oral inoculation
opens up new avenues to further investigate mechanistically how infectious prions can
be taken up by various tissues leading to a catastrophic disease in the brain and what
other alternate transport pathways play a role in facilitating disease pathogenesis.
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